Highlights from ESMO Congress 2024

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 European Society for Medical Oncology Congress with a focus on leukemia. Douglas Tremblay, MD, highlights an abstract related to leukemia at the conference. :29 Douglas Tremblay, MD, discusses another abstract related to leukemia. 5:23 Noah M. Merin, MD, PhD, focuses on recent findings in AML, ALL and MDS presented at the Congress. 9:08 Rosalie Griffin, PhD, discusses her winning poster on biomarker testing in lymphoid malignancies. 12:57 Rosalie Griffin, PhD, also shares her thoughts on a presentation looking at point mutations in lymphoid malignancies. 17:13 Read the full coverage here: https://www.healio.com/news/hematology-oncology/20241009/video-new-car-tcell-product-may-reduce-side-effects-in-all https://www.healio.com/news/hematology-oncology/20241009/video-timdarpacept-examined-in-dedicated-chronic-myelomonocytic-leukemia-trial https://www.healio.com/news/hematology-oncology/20241009/video-no-association-between-point-mutations-and-blood-cancer-precursors https://www.healio.com/news/hematology-oncology/20241009/video-biomarkers-relationship-with-blood-cancers-examined-at-esmo Disclosures: Griffin reports no relevant financial disclosures. Tremblay reports contracted research funding paid to his institution from Cogent Biosciences, Gilead, Sobi and Sumitomo, and consulting fees from AbbVie, Cogent Biosciences, GSK, Novartis, Pharmaessentia, Sierra Oncology and Sobi. Healio could not confirm relevant financial disclosures for Merin at the time of posting.